AcroMeta’s Laboratory Construction Business Rides on Singapore’s Pandemic Readiness Strategy

SINGAPORE, Aug 15, 2023 – (ACN Newswire) – ACROMETA Group Limited, an established specialist engineering service provider in the field of controlled environments serving mainly the healthcare, biotechnology, pharmaceutical, research and academia sectors, announced today that its wholly-owned subsidiary company Acromec Engineers Pte Ltd has been awarded a S$19 million contract for the design and construction of a 1,500 sqm high containment biosafety level research laboratory.

The facility is designed for research on highly infectious pathogens potentially carried by infected animals and spread through airborne transmission.

The state-of-the-art project involves the construction of a high containment biosafety laboratory using modular panels for both reliability and durability to withstand long periods of hard usage and repeated commissioning. Construction would be carried out in a 'live' building with many existing tenants without affecting their operations. The facility is expected to be completed and certified by 2024 and will be compliant with WHO and MOH high containment facility standards.

Mr Lim Say Chin, ACROMETA's Executive Director and Chief Executive Officer, commented: "The award to Acromec is a testament to our engineering experience and capabilities. With its expertise and established track record in controlled environments engineering, AcroMeta is positioned to benefit from the construction of such laboratories as governments in the region strengthen their biomedical R&D capabilities to counter threats from infectious diseases."

Acromec, the wholly-owned engineering subsidiary of the Group, is an established specialist engineering services provider with more than 25 years of experience in the field of controlled environments. It has designed and built several high biosafety level R & D laboratories and manufacturing facilities for biomedical companies, such as 10X Genomics, Integrated DNA Technologies, and GenScript.

Research laboratories a vital link in Singapore's pandemic readiness strategy

Singapore emerged from the Covid-19 pandemic as one of the countries that scored high marks for its handling of the crisis. Every aspect of the pandemic was systematically studied, monitored, and appropriate actions taken – from procurement and cold storage of vaccines for the entire resident population, to laboratory testing and identification of each mutated variant of the virus as it evolved.

But the pandemic also revealed the need for Singapore to be prepared for future pandemics. The government has implemented the findings of the Covid-19 White Paper published on 8 March 2023 which detailed the 7 lessons to be learned from the pandemic and implemented a pandemic readiness strategy. The strategy takes a whole-country approach and involves participation by, and collaboration with the private sector as well as with the entire population.

Mr Levin Lee Keng Weng, ACROMETA's Executive Chairman, added: "Laboratories for the testing, identification and carrying out of research with live virus is a vital link in the Singapore government's preparedness strategy for future pandemics. These laboratories are not standard laboratories but highly specialised facilities; the design and construction of which can only be done by a handful of controlled environments experts such as Acromec."

This media release has been reviewed by the Company's Sponsor, Evolve Capital Advisory Private Limited. It has not been examined or approved by the Singapore Exchange Securities Trading Limited, and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.

The contact person for the Sponsor is Mr. Jerry Chua, 138 Robinson Road, #13-02 Oxley Tower, Singapore 068906, jerrychua@evolvecapitalasia.com.

Reference:
https://links.sgx.com/1.0.0/corporate-announcements/QYHDGZS2TXQ25H0Q/cc60f5adb8665785b09fc0d7833240cd9253d57800c21ff2906079f092b27884

https://links.sgx.com/FileOpen/Acrometa-ProjectWinPressRelease_15Aug2023IDLabs%20-%20Final.ashx?App=Announcement&FileID=769346

About ACROMETA Group Limited (SGX Stock Code:43F)

ACROMETA (Previously known as ACROMEC Limited) is an established specialist engineering services provider with more than 25 years of experience in the field of controlled environments.

The Group has, over the years, acquired expertise in the design and construction of facilities requiring controlled environments such as laboratories, medical and sterile facilities and cleanrooms.

ACROMETA's business is divided into three main business segments: (i) Engineering, procurement, and construction services, specialising in architectural, and mechanical, electrical, and process works within controlled environments; (ii) Maintenance and repair services of facilities and equipment of controlled environments and their supporting infrastructure. (iii) Co-Working Laboratory business; currently operates 6,500 square feet of co-working laboratory space at The German Centre in Singapore, serving SMEs and startups.

The Group mainly serves the healthcare, biotechnology, pharmaceutical, research and academia, and electronics sectors. ACROMETA's customers include hospitals and medical centres, government agencies, research and development companies or agencies, research and development units of multinational corporations, tertiary educational institutions, pharmaceutical companies, semiconductor manufacturing companies, and multinational engineering companies.

The Company has been listed on the Catalist board of the Singapore Exchange since 2016. For more information, please visit www.acrometa.com.

Media and Analysts Contact:

ACROMETA Group Limited
Ms. Cheah Lai Min
Chief Financial Officer
Tel: +65 6415 0574
Email: laimin.cheah@acrometa.com

Waterbrooks Consultants Pte Ltd
Mr. Wayne Koo
Tel: +65 6958 8008 / +65 9338 8166
Email: wayne.koo@waterbrooks.com.sg, query@waterbrooks.com.sg

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Q&M 1H2023 Core Healthcare Revenue stays resilient as the Group focuses on organic growth plans

SINGAPORE, Aug 15, 2023 – (ACN Newswire) – Mainboard-listed Q&M Dental Group (Singapore) Limited ("Q&M", the "Company", and together with its subsidiaries, the "Group") today reported total revenue of S$87.1 million, and profit after tax attributable to parent of S$5.3 million for the first half ended 30 June 2023 ("1H2023"). The Group's earnings before interest, tax, depreciation, amortisation ("EBITDA") for 1H2023 was S$18.5 million.

Core Healthcare Business revenue decreased marginally from S$83.7 million for 1H2022 to S$83.3 million for 1H2023, mainly due to higher revenue contribution from Singapore dental clinics offset by lower revenue contribution from Singapore medical clinics and the impact of the weakening Malaysian Ringgit for the Group's operations in Malaysia. The Group's other business segment ie medical laboratory were impacted by lower demand for Covid-19 testing.

Dr Ng Chin Siau, Group Chief Executive Officer of Q&M, said, "The continual resilience of Q&M's Core Healthcare Business is well appreciated by investors and reflects the Group's well-established foundations. Further, we will focus on organic growth following significant expansion of our dental clinic network across Singapore and Malaysia in 2022. We will continue to invest in technology and implement strategies that will enable us to further optimise productivity across our clinic network."

Recently, Q&M launched its dedicated mobile App on both the Apple Appstore and Google Play. With just the click of a few buttons, a patient can select their preferred date, time and clinic location to make appointments to see the dentist. Q&M's patients can receive timely reminders before the appointment dates and view past and future appointments, reschedule or cancel appointments anytime, as well as manage their digital receipts through the App. Additionally, results of x-rays taken are uploaded into the App for quick reference. The patient will receive a 6-monthly reminder notification when it is time for them to attend their dental check-up, so as to ensure their dental and oral conditions are closely monitored.

Looking ahead

Q&M Group has devised a holistic strategy to foster sustainable growth focusing on organic growth by leveraging on our brand and expertise and capitalising on opportunities to expand our services and reach.

We are working hard to build a strong platform upon which our future growth can be firmly established based on the following 5 thrusts:

1. Building Strong Foundations- strengthening the basics

Our cluster management system is being enhanced with dentists and dental assistants working even more closely together with area managers to optimise both human and physical resource allocation throughout the network.

2. Improving efficiency – reducing costs and wastage

Our Group is mindful of keeping costs low and using central purchasing as much as possible to reduce wastage and ensure more just-in-time ordering so that we can also reduce storage costs correspondingly.

3. Medical Laboratory

Post-pandemic, the Group's medical laboratory business, Acumen Diagnostic will continue to develop its range of tests and solutions to maximise its intellectual property and research capabilities for various medical purposes. These include the tests for sepsis, identification of bacteria pathogens and their associated antimicrobial resistance in hospitalised pneumonia.

4. Expanding our brand- locally and overseas

Beyond Singapore, the Group continues to explore good opportunities to develop a new sustainable growth pillar through organic growth and further expansion of its dental business in Southeast Asia growing private dental healthcare market. We are also exploring the expansion of the Q&M brand and knowhow beyond our current borders. As a premium dental group with a strong reputation for high-quality products and services, we are working towards exporting our expertise regionally and beyond in a deliberate and decisive manner.

Commitment to our Community

Anchored in the Company's philosophy, Q&M Free Dental Clinic Limited, a registered charity under the Commission of Charities, opened its first free dental clinic on 10 July 2023 in Chai Chee, to provide essential dental treatment for the underprivileged individuals and families in need.

This press release is read in conjunction with Q&M's 1H2023 results release on SGXNET.

For more information, please read the attached SGXNET announcement and media release.

https://links.sgx.com/1.0.0/corporate-announcements/N9238L5A9JUG97NG/ca70061aa798c196bcb9132653f9e01c12ad35d1d3327823f3a120d1949a5e95

[1] Core Healthcare Business excludes contributions from the Group?s medical laboratory and expenses incurred on the development of the Group?s digital Artificial Intelligence (AI) guided clinical decision support system as well as rental rebates received from the Singapore Government.

About Q&M Dental Group (Singapore) Limited (QC7.SI)

Q&M Dental Group (Singapore) Limited (QC7.SI) ("Q&M" or together with its subsidiaries, the "Group") is a leading private dental healthcare group in Asia.

The Group owns the largest network of private dental outlets in Singapore, operating 108 dental outlets across the country. Underpinned by about 270 experienced dentists and over 350 supporting staff, the Group sees an average of 40,000 patient visits a month in Singapore. The Group also operates 5 medical clinics and a dental supplies and equipment distribution company.

Outside of Singapore, the Group has 44 dental clinics and a dental supplies and equipment distribution company in Malaysia, as well as a dental clinic in the People's Republic of China ("PRC"). Q&M is also the substantial shareholder of Aoxin Q&M Dental Group Limited, a dental Group listed on the Catalist board of the Singapore Exchange that operates dental clinics and hospitals primarily in the north-eastern region of the PRC. The Group aims to expand its operations geographically and vertically through the value chain in Malaysia, the PRC and within the ASEAN region.

The Q&M College of Dentistry was established in 2019 to offer postgraduate dental education as part of its commitment to continual education and professional development of dentists. It offers Singapore's first private postgraduate diploma programme in clinical dentistry.

In 2020, the Group expanded into the medical laboratories and research industry with the strategic investment into Acumen Diagnostics Pte. Ltd. ("Acumen"). Currently, Acumen focuses on developing its range of medical research, tests and solutions to secure viable patents and to achieve successful commercialisation of the medical products in the near future.

The Group was listed on the Mainboard of the Singapore Exchange Securities Trading Limited ("SGX- ST") on 26 November 2009.

For more information on the Group, please visit www.QandMDental.com.sg

For more information, please contact:
Waterbrooks Consultants Pte Ltd
Wayne Koo: wayne.koo@waterbrooks.com.sg, +65 9338-8166
Derek Yeo: derek@waterbrooks.com.sg, +65 9791-4707
General: query@waterbrooks.com.sg, +65 9690-4959

Proud Investor Relations partner:
https://www.waterbrooks.com.sg/ and https://www.shareinvestorholdings.com/

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

SinoMab Announces that IND Application of SM17 for the Treatment of Asthma was Approved by NAMP

HONG KONG, Aug 14, 2023 – (ACN Newswire) – A Hong Kong-based biopharmaceutical company dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases- SinoMab BioScience Limited (Stock Code: 3681.HK, "SinoMab" or the "Company"), is pleased to announce that the Investigational New Drug ("IND") application, for the treatment of patients with asthma for the Company's First-in-Class (FIC) therapeutic product SM17, was approved by the National Medical Products Administration of China (the "NMPA") on 11 August 2023. The Company plans to conduct a Phase I clinical study in China soon to investigate the safety profile of SM17 in Chinese population and to initiate the clinical development program of SM17 for the treatment of allergic diseases.

SM17 is a novel, first-in-class, humanized, IgG4-k monoclonal antibody which is capable of modulating Type II allergic reaction by targeting the receptor of a critical "alarmin" molecule interleukin 25 (IL-25). SM17 could suppress Th2 immune responses by binding to IL-25 receptor (also known as IL-17RB) on Type 2 Innate Lymphoid cells (ILC2s), and Type 2 helper T (Th2) cells, blocking a cascade of responses induced by IL-25, and suppressing the release of the downstream Th2 cytokines such asIL-4, IL-5 and IL-13. IL-25 is a critical cytokine classified as "alarmin", which has shown to be implicated in the pathogenesis of multiple airway viral responses and allergic diseases, such as asthma. Patients with severe, uncontrolled asthma are at risk of recurrent asthma exacerbations and hospitalizations, and uncontrolled severe asthma is associated with increased mortality and morbidity, diminished quality of life and increased health expenditures.

Meanwhile, the Company is also advancing the Phase I clinical study of SM17 in the U.S. at full speed. Based on the current progress, the Company expects to complete the Phase I clinical study by the end of this year, half a year ahead of the anticipated completion date. As early as March 2022, SM17's IND application for the treatment of asthma was approved by the U.S. Food and Drug Administration ("FDA"), and the first healthy subject had been successfully dosed in a Phase I clinical First-in-Human(FIH) clinical trial in June 2022. As of today, none of the subjects reported a serious adverse event.

As a new pathway for asthma treatment, therapy targeting the upstream mediators of the Th2 inflammatory cascade pathway, such as "alarmin", is expected to have a broad effect on airway inflammation. This is expected to lead to more effective control of asthma symptoms and an improvement in disease conditions compared to existing therapies. This has also been validated in the clinical trial of SM17.

The potential first-in-target antibody of SM17 has demonstrated the potential efficacy for multiple indications, including asthma and IPF (Idiopathic Pulmonary Fibrosis). The above unique mechanism enables SM17 to cover more diversified indications, which can not only target indications with huge market size such as asthma and atopic dermatitis, but also treat diseases with high mortality rate such as IPF, and continuously expand its indication coverage. Compared with other currently approved therapeutic antibody drugs targeting ILC2s downstream pathway, SM17 has a differentiated advantage at the source.

As one of the global pandemics, asthma has caused social problems, with huge and urgent medical needs that cannot be ignored. The number of asthma patients worldwide is increasing year by year, and a large patient base is in urgent need of effective therapeutic drugs to alleviate unmet medical needs. According to the Frost & Sullivan Report, the number of asthma patients worldwide is expected to increase to approximately 860 million in 2030, of which the number of asthma patients in China will increase to 78.1 million which is higher than the global growth rate. The Company expects that targeting upstream mediators of the Th2 inflammatory cascade, such as the receptor for IL-25, will have a broad effect on airway inflammation, which is expected to provide a new therapeutic channel with efficacy and safety for asthma diseases and bring relief and treatment to asthma patients.

Dr. Shui On LEUNG, Executive Director, Chairman and Chief Executive Officer of SinoMab said that: "SM17's IND application for the treatment of asthma has been approved three months after it was accepted by the NMPA, which demonstrates that the efficient execution of the Company's new drug R&D program is well recognized by the NMPA, and also fully reflects the huge potential of SM17 in unmet medical needs for asthma treatment. We are confident in the huge clinical development and commercialization prospects of SM17, and will accelerate the progress of clinical trials and strive to achieve commercial business as soon as possible in the future. At the same time, we continue to expand the scope of indications so that new treatment options can benefit more Chinese patients in the future. The Company will continue to focus on autoimmune diseases, and spare no effort to provide more effective treatment options for Chinese and global patients with abundant technical reserves and strong innovation capabilities."

About SinoMab BioScience Limited
SinoMab BioScience Limited is dedicated to the research, development, manufacturing and commercialization of therapeutics for the treatment of immunological diseases. The R&D headquarters is located in Hong Kong and the production base is located in mainland China. The Company's flagship product SM03 is a potential global first-in-target mAb against CD22 for the treatment of rheumatoid arthritis (RA) and has completed the Phase III clinical trial for rheumatoid arthritis in China, which has been recognized as one of the significant special projects of Significant New Drugs Development of the Twelfth Five-Year Plan Period and the Thirteenth Five-Year Plan Period. In addition, the Company possesses other potential first-in-target and first-in-class drug candidates, some of which are already in clinical stage, with their indications covering rheumatoid arthritis (RA), Alzheimer's disease, systemic lupus erythematosus (SLE), pemphigus (PV), multiple sclerosis (MS), neuromyelitis optica spectrum disorder (NMOSD), non-Hodgkin's lymphoma (NHL), asthma, and other diseases with major unmet clinical needs.

This press release is issued by Financial PR (HK) Limited on behalf of SinoMab BioScience Limited. For further information, please contact:

Financial PR (HK) Limited
Contact: Ms. Chloe Chiu / Ms. Serena Zhang / Ms. Willa Xue
Email: sinomab@financialpr.hk
Tel: (852) 2610 0846
Fax: (852) 2610 0842

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Power-up Your Vacations with LAC

SINGAPORE, Aug 14, 2023 – (ACN Newswire) – Whenever vacation season comes around, surely many of us with holiday plans are impatiently waiting to escape the mundanities of the daily grind and unwind overseas, pronto.

However, while travelling abroad can be an exciting experience, it exposes us to new environments and climates, leading to a higher chance of falling ill from all these jetting around. Research from the Centers for Disease Control and Prevention reveals that as many as 43%-79% of travellers to low- and middle-income countries become ill with a travel-associated health problem. The same study also revealed that travel duration is also a factor as the risk for a travel-associated illness increases with the length of the trip.

To combat these travel-bugs, LAC, Leader in Antioxidative Control, shares these useful travel supplements to pack in your suitcases:

For the Jetlagged and the Sleepyheads

When travelling to destinations of a different timezone, concerns of jetlag and fatigue are commonplace. The misalignment between the body's internal clock and the local time can cause poor sleep quality, causing lowered immunity. LAC Goodnight Powder is formulated with key ingredients such as melatonin, serotonin and Vitamin B6 to regulate the body's circadian rhythm – the perfect sleep supplement for the tired traveller, keeping your immune system right on track to fight off the nasty travel bugs.

For those Prone to Falling Sick

Ever wonder why people tend to fall sick easily while travelling? When visiting destinations that are climatically different from our own, factors such as stress or shifts in lifestyle may expose the body to free radicals which attack the body's immune cells.

To fully savour the sights, flavour and joy of an enjoyable travel experience, reducing the amount of free radicals each of us are exposed to, is important. The LAC MASQUELIER's(R) French Pine Bark Extract is jam-packed with Oligomeric proanthocyanidin complexes (OPCs). These specially-formulated antioxidants reduce the amount of free radicals in the body, allowing the body to combat pathogens and infections effectively.

For the Foodies

The Traveller's Diarrhoea (TD) is one of the most common issues travellers experience during travel. TD is spread mainly through food and water but it can also spread from person to person. While many travellers cite the local cuisine as one of the pulling factors to their holiday destination, being unfamiliar to common bacteria and viruses at their destination are often the primary cause of explosive diarrhoea and loose stools.

The LAC Probiotic Complex 25 Billion CFU would be a suitable solution to mitigate and alleviate the symptoms of TD, making it a perfect daily supplement for foodies who are always in search of the best local delicacies.

All in all, travelling often disrupts our routine and exposes us to different environments, potentially affecting our nutritional intake and immune response. LAC's supplements are a definite travel essential to support your overall health and well-being, ensuring that your body receives the essential nutrients it needs to power up and enjoy the vacation to the max.

About LAC Global

Headquartered in Singapore, LAC Global is one of Asia's largest speciality retailers in nutritional supplements, vitamins, minerals, herbal, and other speciality supplements in Anti-ageing and Beauty, Immunity, Weight Management, Sports Nutrition, and Energy.

The Company owns the LAC brand, short for Leader in Antioxidative Control?, a leading health and wellness supplement brand with a global presence. Since its founding, LAC has embarked on a pioneering journey to develop scientifically based formulas, harnessing the best of eastern wisdom and western technology to fight free radicals, combat ageing brought forth by oxidative stress, and support you daily in looking, feeling, and functioning at your best. Having established a global presence since 1997, LAC's reach includes Singapore, Malaysia, Taiwan, Philippines, China, Japan, Vietnam, Myanmar, USA, Central & South Americas, and the Middle East. Currently, there are more than 220 LAC branded stores in Singapore, Malaysia, Philippines and Taiwan ROC. LAC stringently sources ingredients from around the globe, such as USA, Japan, France, Australia, New Zealand and Switzerland to ensure utmost quality, and works only with the most specialised partners in developing and manufacturing health solutions.

Its other brands include Xndo Food For Health. LAC Global is dedicated to ensuring consumers stay well, and live life to the fullest.

Website: LAC.sg
Instagram: @LACGlobalSingapore
Facebook: @LACGlobalSingapore

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

CanariaBio Announces Enrollment Completion of Phase 2 Study of Oregovomab in Combination with Niraparib in the Treatment of Recurrent Ovarian Cancer

SEOUL, S.KOREA, Aug 8, 2023 – (ACN Newswire) – CanariaBio, a KOSDAQ-listed and a leading late-stage biotechnology company, announces the successful enrollment completion of a Phase 2 study of Oregovomab in combination with niraparib, GSK's poly (ADP-ribose) polymerase (PARP) inhibitor, for treatment of patients with platinum-sensitive recurrent ovarian cancer.

This trial, known as FLORA-4 (NCT05335993), is being conducted by CanariaBio, with GSK providing clinical trial supply of niraparib. The study will assess the immunological and clinical activity, early humoral response, and disease control rate of concomitant Oregovomab and daily oral niraparib. This will be a preliminary investigation of the interaction of indirect immunization with Oregovomab and concomitant niraparib therapy and the immune modulatory effects associated with PARP inhibition. The key aim of the study is to explore whether a non-chemotherapy combination of Oregovomab and niraparib would potentially extend the platinum-free interval, which is known to have a favorable impact on subsequent treatment with platinum-based combination chemotherapy.

Ovarian cancer is known for its high recurrence rate. In this difficult landscape, Oregovomab has the potential of emerging as a promising immunotherapeutic agent. Through rigorous Phase II clinical trials, Oregovomab has not only demonstrated its safety profile but also showcased remarkable results by extending PFS by approximately 30 months when combined with chemotherapy, compared to conventional chemotherapy alone.

About Oregovomab

Oregovomab is a murine monoclonal antibody against CA 125, a biomarker commonly found in ovarian cancer. Indirect immunization with Oregovomab interacts with immune-modulating properties of infused paclitaxel and carboplatin, resulting in synergistic clinical benefits as observed in a Phase II trial. In a randomized Phase II clinical trial of 97 patients, treatment with Oregovomab in combination with chemotherapy had demonstrated a highly statistically significant and clinically meaningful outcome for both progression-free and overall survival compared to standard-of-care chemotherapy (carboplatin and paclitaxel). The risk of progression and of death was reduced by more than 50% when compared to control arm, and safety data showed that Oregovomab did not add incremental toxicity to the chemotherapy regimen. Clinical and translational results were published in Gynecology Oncology (2020) 156:523-529 and Cancer Immunology and Immunotherapy (2020) 69: 383-397, respectively.

About ZEJULA (niraparib)

Niraparib is an oral, once-daily poly (ADP-ribose) polymerase inhibitor approved by FDA and EMA for the use in ovarian cancer, marketed as ZEJULA by GSK. Niraparib is currently being evaluated in multiple pivotal trials. GSK is building a robust clinical development programme by assessing activity across multiple tumour types and evaluating several potential combinations of niraparib with other therapeutics. For questions or more information on niraparib, please visit www.gsk.com.

About CanariaBio Inc.

CanariaBio Inc. is a Korean biopharmaceutical company focused on the development and commercialization of immunotherapies for cancer. CanariaBio's technology platform includes a portfolio of tumor antigen-specific monoclonal immunoglobulins targeting CA-125, MUC1, PSA and Her2/neu. The company is exploring the therapeutic potential of these antibodies as indirect immunizers in combination with other immune-modulating drugs or drug combinations to address unmet medical needs in oncology.

Forward-Looking Statements

This press release includes forward-looking statements. In some cases, forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based on management's expectations and assumptions as of the date of this press release and are subject to a number of risks and uncertainties, many of which are difficult to predict, that could cause actual results to differ materially from current expectations and assumptions from those set forth or implied by any forward-looking statements. The information in this release is provided only as of the date of this release and the company undertakes no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.

Contact Information
Jacquelyn Choi
PR Manager
ipr@canariabio.com

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Men in Relationship – Is Maintaining a Trim Waistline an Uphill Battle? LAC LeanCut(TM) Belli Lean and LAC Mega Maca

SINGAPORE, Aug 7, 2023 – (ACN Newswire) – Many of us often joke about our friends when they get into a relationship, "Did you gain weight? Wow, you must be having a very loving partner now!"

The start of dating and relationships often bring forth happiness between partners, eager to shower time and love on each other. More often than not, from the times spent eating out and enjoying each other's company, men find themselves gaining weight during such wonderful times.

Furthermore, as the relationship progresses on to the next level, marriage, and children come into the picture. Suddenly, combined with a hectic work schedule, there is simply no more time for a quick run or gym sessions anymore.

As time passes, we may have noticed their jeans are running tighter, or heard them lament over feeling tired and more lethargic as compared to the past. Before we let our minds run wild ? is he tired of the relationship!? ? more often than not, the lack of energy is directly related to weight gain.

LAC (Leader in Antioxidative Control) offers nutritional, thoughtful gifts you can shower our men with, to combat excessive weight gain and promote healthy living through the LAC LeanCut(TM) Belli Lean and LAC Mega Maca.

Weight gain occurs when the amount of calories consumed exceeds the calories burned. With the additional food our men have to constantly finish up for us, the excess calories consumed will eventually be stored and accumulated as fat around the abdominal area. An unhealthy accumulation of belly fat puts men more at risk of health problems such as Type 2 diabetes, heart disease, and colorectal cancers. Furthermore, the additional weight gained leaves them feeling more fatigued than usual, which could hamper their usual performance and focus.

LAC LeanCut(TM) Belli Lean not only aims to reduce water retention and subcutaneous fats under the skin, it can also reduce visceral fats that wrap around their organs. Offering a proprietary blend of ingredients such as Corn Silk Extract, Lemon Balm Extract, Red Vine Leaf Extract, Lotus Leaf Extract, Eucommia Leaf Extract and Medium Chain Triglycerides, LAC LeanCut(TM) Belli Lean aims to trim those stubborn inches easily and effectively.

Aside from the LeanCut(TM) Belli Lean, LAC Mega Maca is another supplement that can help our men in relieving fatigue, giving them more energy to survive the day. Containing Maca root as one of the key ingredients, this powerful and invigorating men's tonic promotes men's hormonal balance and nourishes men's vitality health, a convenient alternative for our men to increase their libido and maintain overall health.

About LAC Global

Headquartered in Singapore, LAC Global is one of Asia's largest speciality retailers in nutritional supplements, vitamins, minerals, herbal, and other speciality supplements in Anti-ageing and Beauty, Immunity, Weight Management, Sports Nutrition, and Energy.

The Company owns the LAC brand, short for Leader in Antioxidative Control(TM), a leading health and wellness supplement brand with a global presence. Since its founding, LAC has embarked on a pioneering journey to develop scientifically based formulas, harnessing the best of eastern wisdom and western technology to fight free radicals, combat ageing brought forth by oxidative stress, and support you daily in looking, feeling, and functioning at your best. Having established a global presence since 1997, LAC's reach includes Singapore, Malaysia, Taiwan, Philippines, China, Japan, Vietnam, Myanmar, USA, Central & South Americas, and the Middle East. Currently, there are more than 220 LAC branded stores in Singapore, Malaysia, Philippines and Taiwan ROC. LAC stringently sources ingredients from around the globe, such as USA, Japan, France, Australia, New Zealand and Switzerland to ensure utmost quality, and works only with the most specialised partners in developing and manufacturing health solutions.

Its other brands include Xndo Food For Health. LAC Global is dedicated to ensuring consumers stay well, and live life to the fullest.

Website: LAC.sg
Instagram: @LACGlobalSingapore
Facebook: @LACGlobalSingapore

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Kingworld Medicines Expects 1H Profit Increased By 35%-40%

HONG KONG, Aug 2, 2023 – (ACN Newswire) – Kingworld Medicines Group ("Kingworld Medicines" or the "Group", stock code: 01110.HK), a leading healthcare distribution company, announced a projected rise in profit for the first half of the fiscal year. Based on a preliminary assessment of the unaudited consolidated management accounts of the Group for the six months ending June 30, 2023, the Group anticipates a profit surge ranging from approximately 35% to 40% for the period, compared to the same period last year.

The Board attributes this profit increase to increased revenue and gross profit stemming from the distribution of imported branded pharmaceutical and healthcare products in China, with growth rates reaching approximately 30% to 35% and 15% to 20%, respectively. Additionally, the Group's share of profit from a joint venture saw a boost of approximately 55% to 60% compared to the same period last year. This surge is attributed to the market recovery after the COVID-19 pandemic control measures.

Kingworld Medicines is a company specializing in the distribution of imported branded pharmaceutical and healthcare products in China. The Group adeptly navigated post-pandemic market changes, propelling business expansion by leveraging its industry strengths.

Mr. Zhao Lisheng, Chairman of the Board of Kingworld Medicines Group, commented: "The Group's profit increase was mainly due to market recovery and the Group's employees' unremitting efforts, which adapted post-pandemic. The Group's strengths lie in its strong capabilities in distributing pharmaceutical and healthcare products and its acute insights into the market. Besides, the Group has achieved long-term steady growth by continuously improving efficiency and expanding its business."

Looking ahead, Kingworld Medicines Group will continue to focus on increasing market share, expanding business coverage, and improving efficiency to further enhance the company's profitability and market competitiveness.

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Go Bigger, Go Smarter with Amazfit Bip 5

KUALA LUMPUR, Aug 2, 2023 – (ACN Newswire) – Zepp Health Corporation (Zepp, NYSE: ZEPP), a leading specialist in smart wearables and health technology, proudly announces the global debut of its latest innovation, the Amazfit Bip 5. Boasting the most substantial screen among global offerings, the Amazfit Bip 5 is the first in the Bip series to integrate the versatile Zepp OS. This feature-rich smartwatch sets a new benchmark in user experience, far exceeding expectations for entry-level devices.

Student of Oneworld Hanxin College, Ms. Michelle Yoong, praises the Amazfit Bip 5's affordability and customization features. "The cream white of the Amazfit Bip 5 is simply stunning. For a budget-conscious student like me, it offers excellent value. The large screen perfectly displays all critical information, from my personal data to direct messages and more. Moreover, with over 70 stylish watch faces, it offers impressive customisation options, even allowing me to upload personal photos to the watch. It's fantastic!"

Ms. Cassandra, an executive at The Interview Media Group, lauds the Amazfit Bip 5's practicality. She shares, "The built-in microphone and speaker enable Bluetooth phone calls directly from the watch, streamlining my life significantly. It also monitors my health, gives reminders and tracks menstrual cycle, which is invaluable during my fast-paced work week."

The Amazfit Bip 5 sports a 1.91" ultra-large high-resolution touchscreen and the cutting-edge Zepp OS 2.0, supporting 70+ apps, including 30+ mini games. Other smart features like Amazon Alexa, Morning updates, and a slightly curved glass screen, for a more natural view, enhance the user experience. It even supports a Portrait Watch Face option, allowing users to switch to up to three uploaded pictures.

As the most advanced smartwatch in the Bip series, the Amazfit Bip 5 leverages the health-focused Zepp OS 2.0 and the BioTracker(TM) PPG sensor, enabling 24-hour blood oxygen saturation monitoring, along with heart rate and stress levels. Users can set alerts for these three metrics and are notified if abnormal readings are detected.

The Amazfit Bip 5 doesn't hold back when it comes to fitness, featuring over 120 workout modes. Users can auto-detect seven sports, or access real-time sports data read-outs via the built-in speaker for a smarter workout experience.

Even after the workout, the Amazfit Bip 5 continues to impress. The incorporation of Amazfit's PeakBeats(TM) algorithm offers a detailed analysis of exercise data like VO2 Max. Users can then share this information with fitness apps like adidas Running and Strava, through the Zepp App.

From 5-8 August, the Amazfit Bip 5 is exclusively available on Shopee at a special launch price of RM319 for the first 200 Bip 5, with the price set at RM329 thereafter.

Availability

All featured Amazfit products are available for purchase at Amazfit's e-commerce partner platform https://bit.ly/Amazfit-Shopee-BIP5 and https://bit.ly/Amazfit-Lazada-BIP5.

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com

Healthcare Hiring on the rise in the Philippines: foundit Insights Tracker

Despite a slight dip in the country’s annual hiring activity, healthcare and retail continue to offer promising job opportunities.
Healthcare professionals lead all other industry job roles charting the highest annual growth of 21% in June ‘23

MANILA, Aug 2, 2023 – (ACN Newswire) – foundit (formerly Monster APAC & ME), one of the leading talent platforms, today published the foundit Insights Tracker (fit) for June 2023, formerly published as Monster Employment Index (MEI). According to the Philippines fit report, job roles in the Healthcare and Retail sector have impressively grown by 26% and 12% respectively over the past year.

The tracker also reveals a marginal dip of 2% in e-recruitment activity, as the index climbed down from 127 in June 2022 to 124 in June 2023. Despite this drop in recruitment activity, sectors such as Healthcare, Retail, and BPO/ITES witnessed progressive annual hiring growth in June’23. Amidst the ongoing pursuit of cost-cutting measures by global businesses, call centers and outsourcing companies in the Philippines have exceeded revenue and hiring targets and managed to maintain a positive outlook for the BPO job market. These promising numbers confirm a gradual but continuous improvement in the labour market, implying that demand for online recruitment will continue to climb in the coming months.

Commenting on the Philippines job trends for June 2023, Sekhar Garisa, CEO, foundit, said, “Hiring is picking up pace in the Philippines. We are hopeful that jobs will rebound in the upcoming months as certain sectors such as Healthcare, Retail, and BPO/ITES are showing a positive growth trajectory. The Philippines government has also shown support for gig & hybrid jobs, boosting hiring for service. This is crucial for job seekers, as it gives them more flexibility and opportunities to work in different sectors and locations.”

Healthcare, Retail, and BPO/ITES sectors lead in hiring activity, while the IT, Telecom, Logistics, Courier/Freight, and Advertising industries witness a drop in recruitment.

The fit reveals that the Healthcare industry continued to dominate the job market in June 2023, with a YoY increase of 26% hiring in the sector. Despite the shortage of skilled nurses and doctors, there has been a promising upward trend in hiring efforts to meet the country’s healthcare demands. Also, the Retail industry (+12%) witnessed double-digit growth in hiring demand this month owing to the increased number of customers visiting physical stores. Given that the Filipino government had allowed BPO companies with work-from-home arrangements to retain tax incentives, the hiring in the BPO/ITES sector (+11%) saw sequential annual growth in June ’23.

The Logistics, Courier/Freight/Transportation, and Shipping industry along with IT and Telecom/ISP has recorded a dramatic decline in hiring activity, with a YoY decrease of 34% and 20% respectively. Logistics has always presented a major challenge in the Philippines due to inadequate infrastructure, frequent weather-related disasters, and scattered demand. Consequently, the industry has struggled to thrive, resulting in sluggish hiring trends within the sector. The growth momentum for other industries such as Advertising, MR, PR, Media & Entertainment (-18%), Engineering, Construction and Real Estate (-1%), Hospitality (-3%), BFSI (-13%), Production/Manufacturing, Automotive and Ancillary (-14%), and Education (-17%) saw a consecutive dip annually in June’23.

Roles in Healthcare, Sales & Business Development, and Customer Service lead the hiring trends

There continues to be a high demand for Healthcare (+21%) professionals marking the steepest annual growth in June’23. With the sudden jump in the retail sector, the jobs in Sales & Business Development (+17%) went up leading to increase in demand for candidates Customer service and software, hardware, and telecom functions are also experiencing positive and steady growth of 11% and 3%, respectively, due to the improving economy.

Jobs in Purchase/ Logistics/ Supply chain (-24%) have been facing some challenges since Jan’23 and showed the lowest growth in hiring this month among all monitored functions. Hiring for Marketing & Communications (-21%) and HR & Admin (-21%) roles too dipped substantially in June’23. Other industries to witness a subsequent drop in hiring activity include – Hospitality & Travel (-1%) Engineering/ Production, Real Estate (-2%), and Finance and Accounts (-10%).

The foundit Insights Tracker is a comprehensive monthly analysis of online job posting activity conducted by foundit. Based on a real-time review of millions of employer job opportunities culled from a large, representative selection of online career outlets, the foundit Insights Tracker (fit) presents a snapshot of employer online recruitment activity nationwide.

Period for the report

The period considered for the foundit Insights Tracker (fit) data is June 2022 vs. June 2023.

About foundit – APAC & Middle East

foundit, formerly Monster (APAC & ME), is a leading talent platform offering comprehensive employment solutions to recruiters and job seekers across APAC & ME. Since its inception, the company has assisted over 75 million registered users to find jobs, upskill, and connect with the right opportunities across 18 countries. Over the last two decades, the company has been a catalyst in the world of recruitment solutions with advanced technology, seeking to efficiently bridge the talent gap across industry verticals, experience levels, and geographies. Today, foundit is committed to enabling and connecting the right talent with the right opportunities by harnessing the power of deep tech to sharpen hyper-personalized job searches, and precision hiring. foundit strongly believes that a job title doesn’t define one’s potential and leverages technology to dig deeper to curate opportunities central to the needs and aspirations of each user.

To learn more, about foundit in APAC & Gulf,

Contact:
Namrata Sharma
Namrata.sharma@adfactorspr.com
+6581383034

Vasileios Mingos Joins Health-ISAC as European Operations Director

ORMOND BEACH, FL, Aug 1, 2023 – (ACN Newswire) – Health Information Sharing and Analysis Center (Health-ISAC) has announced Vasileios Mingos has joined the organization and will serve as European Operations Director. Mingos will oversee all Health-ISAC European Operations, the European Regional Threat Operations Center, and represent Health-ISAC throughout Europe.

In his role, Mingos will continue to expand a regional Health-ISAC presence in Europe by collaborating directly with member organizations, including some of the world's largest healthcare firms. In addition, he will develop and enhance partnerships with key regional stakeholders such as industry associations, government agencies, CERTs, and law enforcement.

"We are excited to bring Vasileios onboard for this important mission," says Denise Anderson, President and CEO of Health-ISAC. "He brings a passion as well as deep experience in healthcare cybersecurity to the position. Having him as part of the global team helps solidify Health-ISAC's commitment to securing healthcare globally and serving our members and the health sector in Europe."

Mingos has a strong background in building and leading information security teams since 2017 and his previous work experience includes developing and implementing Eurofins' Security Operations Center and Security Intelligence program in Europe.

ABOUT HEALTH-ISAC

Health-ISAC – a non-profit, private sector, member-driven organization – plays an essential role in providing situational awareness around cyber and physical security threats to the Healthcare Sector so that companies can detect, mitigate, and respond to ensure operational resilience. Health-ISAC connects thousands of healthcare security professionals worldwide to share peer insights, real-time alerts, and best practices in a trusted, collaborative environment. As the go-to source for timely, actionable, and relevant information, Health-ISAC is a force-multiplier that enables healthcare organizations of all sizes to enhance situation awareness, develop effective mitigation strategies and proactively defend against threats every single day.

Contact Information:
Julia Annaloro
Marketing and Communications II
contact@h-isac.org
+1-321-593-1470

Copyright 2023 ACN Newswire. All rights reserved. http://www.acnnewswire.com